A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality.
Experimental and Clinical Psychopharmacology · 2024-06 · 32 (3) · 277-284
DOI: 10.1037/pha0000682 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Experimental and Clinical Psychopharmacology, 2024-06. Verfasst von Marcel O Bonn-Miller und 8 weiteren Autor:innen. Beteiligte Einrichtung: Canopy Growth Corporation. Hauptthemen laut MEDLINE: Sleep Quality, Cannabidiol. Die Arbeit wurde bisher 32-mal zitiert (Crossref). Gefördert von: Canopy Growth Corporation.
Themen: Schlaf
Abstract (Originalsprache)
The present study sought to determine the effects of cannabinol (CBN) alone and in combination with cannabidiol (CBD) on sleep quality. This was a double-blind, randomized, placebo-controlled study conducted between May and November 2022. Participants were randomized to receive either (a) placebo, (b) 20 mg CBN, (c) 20 mg CBN + 10 mg CBD, (d) 20 mg CBN + 20 mg CBD, or (e) 20 mg CBN + 100 mg CBD for seven consecutive nights. Participants were 18-55 years of age who self-rated sleep quality as "very poor" or "poor." The primary endpoint was sleep quality, while secondary endpoints included sleep onset latency, number of awakenings, wake after sleep onset (WASO), overall sleep disturbance, and daytime fatigue. In a modified intent-to-treat analyses (N = 293), compared to placebo, 20 mg CBN demonstrated a nonsignificant but potentially meaningful effect on sleep quality (OR [95% CI] = 2.26 [0.93, 5.52], p = .082) and significantly reduced number of awakenings (95% CI [-0.96, -0.05], p = .025) and overall sleep disturbance (95% CI [-2.59, -0.14], p = .023). There was no difference from placebo among any group for sleep onset latency, WASO, or daytime fatigue (all p > .05). Individuals receiving 20 mg CBN demonstrated reduced nighttime awakenings and overall sleep disturbance relative to placebo, with no impact on daytime fatigue. The addition of CBD did not positively augment CBN treatment effects. No differences were observed for latency to sleep onset or WASO. Findings suggest 20 mg of CBN taken nightly may be helpful for improving overall sleep disturbance, including the number of times one wakes up throughout the night, without impacting daytime fatigue. (PsycInfo Database Record (c) 2024 APA, all rights reserved).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Canopy Growth Corporation.
- Wana Brands.
Förderung
- Canopy Growth Corporation
Zitieren
APA
Bonn-Miller, M. O., Feldner, M. T., Bynion, T. M., Eglit, G. M. L., Brunstetter, M., Kalaba, M., Zvorsky, I., Peters, E. N., & Hennesy, M. (2024). A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Experimental and Clinical Psychopharmacology, 32(3), 277-284. https://doi.org/10.1037/pha0000682
Vancouver
Bonn-Miller MO, Feldner MT, Bynion TM, Eglit GML, Brunstetter M, Kalaba M, et al. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Experimental and Clinical Psychopharmacology. 2024;32(3):277-284. doi:10.1037/pha0000682
BibTeX
@article{BonnMiller2024,
author = {Bonn-Miller, Marcel O and Feldner, Matthew T and Bynion, Teah M and Eglit, Graham M L and Brunstetter, Megan and Kalaba, Maja and Zvorsky, Ivori and Peters, Erica N and Hennesy, Mike},
title = {A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality},
journal = {Experimental and Clinical Psychopharmacology},
year = {2024},
volume = {32},
number = {3},
pages = {277--284},
doi = {10.1037/pha0000682}
}
EUVIMED